NCT00570193

Photodynamic and Pharmacologic Treatment of CNV

Photodynamic and Pharmacologic Treatment of Choroidal Neovascularization (Photodynamic Booster Study)

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 41 (actual)
• Sponsor: Mid-Atlantic Retina Consultations, Inc. · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The goal of this pilot study is to validate the use of the combination of Lucentis (ranibizumab) and Visudyne (verteporfin) in the treatment of choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) and to explore the use of a volumetric analysis of the CNV lesion to determine disease activity, response to therapy, and as a tool for determining the need for retreatment.

Conditions

• Choroidal Neovascularization
• Macular Degeneration

Interventions

Type	Name	Description
DRUG	verteporfin (Visudyne)	Verteporfin (Visudyne) 6 mg/m2 at 300mW/cm2 given on week O and then at week 5, given as indicated per protocol; ranibizumab (Lucentis) 0.3 mg given at week 1
DRUG	ranibizumab (Lucentis)	ranibizumab (Lucentis) 0.3 mg on weeks 1,5,9,13,17,21,25,29,33\&37 per study protocol

Timeline

• Start date: 2006-12-01
• Primary completion: 2011-06-01
• Completion: 2011-06-01
• First posted: 2007-12-10
• Last updated: 2012-07-10